Literature DB >> 36063190

Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation.

Mark D Murphey1,2,3, Matthew J Minn4,5,6, Alejandro Luiña Contreras7, Kelly K Koeller4,8, Robert Y Shih4,9,5, Carrie Y Inwards10, Takehiko Yamaguchi11.   

Abstract

Benign notochordal cell tumor (BNCT) and chordoma are neoplasms of notochordal differentiation. BNCT represents notochordal rests, commonly an incidental lesion present in the spine in 19% of cadaveric specimens. BNCTs are often radiographically occult. CT of BNCT frequently reveals patchy sclerosis between areas of maintained underlying trabeculae. BNCT demonstrates marrow replacement on T1-weighted MR images with high signal intensity on T2-weighting. BNCTs are frequently smaller than 35 mm and lack significant enhancement, bone destruction, cortical permeation, or soft tissue components. Biopsy or surgical resection of BNCT is usually not warranted, although imaging surveillance may be indicated. Chordoma is a rare low-grade locally aggressive malignancy representing 1-4% of primary malignant bone tumors. Chordoma is most frequent between the ages of 50-60 years with a male predilection. Clinical symptoms, while nonspecific and location dependent, include back pain, numbness, myelopathy, and bowel/bladder incontinence. Unfortunately, lesions are often large at presentation owing to diagnosis delay. Imaging of chordoma shows variable mixtures of bone destruction and sclerosis, calcification (50-70% at CT) and large soft tissue components. MR imaging of chordoma reveals multilobulated areas of marrow replacement on T1-weighting and high signal intensity on T2-weighting reflecting the myxoid component within the lesion and areas of hemorrhage seen histologically. Treatment of chordoma is primarily surgical with prognosis related to resection extent. Unfortunately, complete resection is often not possible (21-75%) resulting in high local recurrence incidence (19-75%) and a 5-year survival rate of 45-86%. This article reviews and illustrates the clinical characteristics, pathologic features, imaging appearance spectrum, treatment, and prognosis of BNCT and spinal chordoma.
© 2022. The Author(s), under exclusive licence to International Skeletal Society (ISS).

Entities:  

Keywords:  Benign notochordal cell tumor; Chordoma; WHO classification

Year:  2022        PMID: 36063190     DOI: 10.1007/s00256-022-04158-7

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.128


  35 in total

1.  Dedifferentiated Chordoma: Clinicopathologic and Molecular Characteristics With Integrative Analysis.

Authors:  Yin P Hung; Julio A Diaz-Perez; Gregory M Cote; Johan Wejde; Joseph H Schwab; Valentina Nardi; Ivan A Chebib; Vikram Deshpande; Martin K Selig; Miriam A Bredella; Andrew E Rosenberg; G Petur Nielsen
Journal:  Am J Surg Pathol       Date:  2020-09       Impact factor: 6.394

2.  Atypical Notochordal Cell Tumors: A Series of Notochordal-derived Tumors That Defy Current Classification Schemes.

Authors:  Jodi M Carter; Doris E Wenger; Peter S Rose; Carrie Y Inwards
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

3.  Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population.

Authors:  Mary L McMaster; Alisa M Goldstein; Dilys M Parry
Journal:  J Med Genet       Date:  2011-01-25       Impact factor: 6.318

Review 4.  Retroclival ecchordosis physaliphora: MR imaging and review of the literature.

Authors:  Florian Mehnert; Rudi Beschorner; Wilhelm Küker; Ulrich Hahn; Thomas Nägele
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

5.  MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions.

Authors:  Florian Grabellus; Margarethe J Konik; Karl Worm; Sien-Yi Sheu; Johannes A P van de Nes; Sebastian Bauer; Werner Paulus; Rupert Egensperger; Kurt W Schmid
Journal:  Tumour Biol       Date:  2010-03-06

Review 6.  Poorly differentiated chordoma: review of 53 cases.

Authors:  H Gokce Yeter; Kemal Kosemehmetoglu; Figen Soylemezoglu
Journal:  APMIS       Date:  2019-09       Impact factor: 3.205

7.  Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population.

Authors:  Nicolas R Smoll; Oliver P Gautschi; Ivan Radovanovic; Karl Schaller; Damien C Weber
Journal:  Cancer       Date:  2013-03-15       Impact factor: 6.860

8.  Clinicopathologic characteristics of poorly differentiated chordoma.

Authors:  Angela R Shih; Gregory M Cote; Ivan Chebib; Edwin Choy; Thomas DeLaney; Vikram Deshpande; Francis J Hornicek; Ruoyu Miao; Joseph H Schwab; G Petur Nielsen; Yen-Lin Chen
Journal:  Mod Pathol       Date:  2018-02-26       Impact factor: 7.842

9.  Chordoma. A clinicopathologic and prognostic study of a Swedish national series.

Authors:  B Eriksson; B Gunterberg; L G Kindblom
Journal:  Acta Orthop Scand       Date:  1981-02

Review 10.  Chordoma.

Authors:  Veronica Ulici; Jesse Hart
Journal:  Arch Pathol Lab Med       Date:  2022-03-01       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.